Brugada Syndrome in the Inpatient Setting: Clinical Diagnosis and Management Strategies for the H... скачать в хорошем качестве

Brugada Syndrome in the Inpatient Setting: Clinical Diagnosis and Management Strategies for the H...

In this episode of Hospital Medicine Unplugged, we sprint through Brugada syndrome—spot the ECG, stratify the risk, prevent sudden cardiac death, and avoid the triggers that unmask malignant arrhythmias. We start with the ECG that makes the diagnosis. Type 1 Brugada pattern is the only diagnostic finding: coved ST elevation ≥2 mm in ≥1 right precordial lead (V1–V3) followed by a negative T wave. The 2013 consensus simplified the diagnosis—a Type 1 pattern alone (spontaneous or drug-induced) is sufficient, without requiring symptoms or family history. Type 2 (“saddleback”) pattern shows ≥0.5 mm ST elevation with a convex ST segment and positive T wave, but it is only suggestive, not diagnostic. Next comes a critical inpatient pearl: Brugada ECG patterns are dynamic. They may appear and disappear and are often unmasked by fever, sodium-channel blockers, increased vagal tone, or post-prandial states. This is why hospitalized patients with unexplained syncope or fever should have careful ECG review—the pattern may only be visible transiently. Risk stratification drives management and ICD decisions, which is one of the hardest parts of Brugada care. High-risk patients (Class I indication for ICD): • Prior cardiac arrest or documented sustained ventricular arrhythmia • Spontaneous Type 1 ECG with syncope presumed due to ventricular arrhythmia These patients face annual event rates of roughly 5–10%, making ICD therapy life-saving. Intermediate risk: • Asymptomatic spontaneous Type 1 pattern (≈0.5–1.2% annual risk) • Syncope with spontaneous Type 1 pattern (≈6–19% event risk over ~2–3 years) • Fever-induced Type 1 ECG pattern Low risk (ICD not indicated): • Asymptomatic patients with only drug-induced Type 1 pattern • Event rate ＜0.5% annually A key myth to bust: family history alone does NOT reliably predict individual arrhythmic risk. We also review BRUGADA-RISK, a modern clinical risk model incorporating ECG and clinical variables to estimate 5-year arrhythmic risk, showing strong predictive performance with ~71% sensitivity and ~80% specificity at a 10% risk threshold. Then comes the debate over electrophysiology studies (EPS). Current guidelines give Class IIb support for programmed ventricular stimulation in asymptomatic patients with spontaneous Type 1 ECG. Inducible arrhythmias roughly double the risk of events, but the absence of inducibility does not guarantee safety, so clinical history still matters most. When prevention matters most, remember the bottom line: ICD implantation is the only proven therapy that prevents sudden cardiac death in Brugada syndrome. Class I indications for ICD: • Survivors of cardiac arrest • Documented spontaneous sustained VT • Spontaneous Type 1 ECG with arrhythmic syncope For patients with recurrent ICD shocks, escalation strategies include quinidine therapy or catheter ablation targeting abnormal epicardial substrate in the RV outflow tract. Hospital teams must also know the medications that worsen Brugada. Drugs that block cardiac sodium channels can unmask the ECG pattern and trigger ventricular arrhythmias. High-risk categories include Class IC antiarrhythmics (flecainide, propafenone), tricyclic antidepressants, lithium, certain antipsychotics, local anesthetics like bupivacaine, propofol, cocaine, and excessive alcohol. The safest move is to check brugadadrugs.org before prescribing. Finally, one of the most important bedside pearls: fever is a powerful arrhythmic trigger in Brugada syndrome. Temperature-dependent sodium channel dysfunction can convert a silent patient into a ventricular arrhythmia emergency. That’s why aggressive antipyretic therapy is mandatory in any febrile Brugada patient—especially in children and hospitalized patients. We close with the take-home system moves: recognize the Type 1 ECG pattern, treat fever aggressively, avoid sodium-channel-blocking medications, risk-stratify carefully, and implant ICDs in the right patients. Brugada syndrome may hide in plain sight—but once you know the ECG and the triggers, you can identify risk early and prevent sudden cardiac death.